浏览全部资源
扫码关注微信
上海中医药大学附属龙华医院肾病科(上海 200032)
张琳俪,女,硕士研究生,主要从事尿酸性肾病相关研究工作
张先闻,主任医师,硕士研究生导师; E-mail: zxw0202@163.com
纸质出版日期:2024-09-10,
收稿日期:2023-08-09,
移动端阅览
张琳俪,王琳,陈以平,等.中药治疗尿酸性肾病的研究进展[J].上海中医药杂志,2024,58(9):96-101.
ZHANG Linli,WANG Lin,CHEN Yiping,et al.Research progress on traditional Chinese herbal medicine in treatment of uric acid nephropathy[J].Shanghai Journal of Traditional Chinese Medicine,2024,58(9):96-101.
张琳俪,王琳,陈以平,等.中药治疗尿酸性肾病的研究进展[J].上海中医药杂志,2024,58(9):96-101. DOI: 10.16305/j.1007-1334.2024.2308032.
ZHANG Linli,WANG Lin,CHEN Yiping,et al.Research progress on traditional Chinese herbal medicine in treatment of uric acid nephropathy[J].Shanghai Journal of Traditional Chinese Medicine,2024,58(9):96-101. DOI: 10.16305/j.1007-1334.2024.2308032.
综述中药治疗尿酸性肾病的研究进展。近年研究发现,在尿酸性肾病治疗中,中药复方及单味药在减少尿酸盐沉积、抗氧化、保护内皮细胞、改善炎症反应等方面发挥了保护肾功能的作用,为进一步优化尿酸性肾病临床治疗方案提供了思路。
The research progress on traditional Chinese herbal medicine in the treatment of uric acid nephropathy is reviewed. In recent years, researches have found that in the treatment of uric acid nephropathy, traditional Chinese medicine formulas and single drugs have played a protective role in reducing urate deposition, antioxidation, protecting endothelial cells, and improving inflammatory response, providing ideas for further optimizing the clinical plan of uric acid nephropathy.
尿酸性肾病高尿酸血症慢性肾脏病病因病机作用机制中药研究
uric acid nephropathyhyperuricemiachronic kidney diseaseetiology and pathogenesismechanism of actiontraditional Chinese herbal medicine research
ZHANG M, ZHU X, WU J, et al. Prevalence of hyperuricemia among Chinese adults: Findings from two nationally representative cross-sectional surveys in 2015-16 and 2018-19[J]. Front Immunol, 2022, 12: 791983.
LIN B, SHAO L, LUO Q, et al. Prevalence of chronic kidney disease and its association with metabolic diseases: a cross-sectional survey in Zhejiang province,Eastern China[J]. BMC Nephrol, 2014, 15: 36.
SU H Y, YANG C, LIANG D, et al. Research advances in the mechanisms of hyperuricemia-induced renal injury[J]. Biomed Res Int, 2020, 2020: 5817348.
TSUKAMOTO S I, WAKUI H, TAMURA K. Effects of uric acid-lowering therapy on the kidney(HTR-2023-0096.R2)[J]. Hypertens Res, 2023, 46(6): 1447-1449.
YANAI H, ADACHI H, HAKOSHIMA M, et al. Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease[J]. Int J Mol Sci, 2021, 22(17): 9221.
KUWABARA M, KODAMA T, AE R, et al. Update in uric acid, hypertension, and cardiovascular diseases[J]. Hypertens Res, 2023, 46(7): 1714-1726.
ADOMAKO E A, MOE O W. Uric acid transport, transporters,and their pharmacological targeting[J]. Acta Physiol(Oxf), 2023, 238(2): e13980.
LIPKOWITZ M S. Regulation of uric acid excretion by the kidney[J]. Curr Rheumatol Rep, 2012, 14(2): 179-188.
WU S, KONG M, SONG Y, et al. Ethnic disparities in bidirectional causal effects between serum uric acid and kidney function: Trans-ethnic mendelian randomization study[J]. Heliyon, 2023, 9(11): e21108.
KUMAGAI T, OTA T, TAMURA Y, et al. Time to target uric acid to retard CKD progression[J]. Clin Exp Nephrol, 2017, 21(2): 182-192.
MIAKE J, HISATOME I, TOMITA K, et al. Impact of hyper- and hypo-uricemia on kidney function[J]. Biomedicines, 2023, 11(5): 1258.
ZHEN H, GUI F. The role of hyperuricemia on vascular endothelium dysfunction[J]. Biomed Rep, 2017, 7(4): 325-330.
SANCHEZ-LOZADA L G, RODRIGUEZ-ITURBE B,KELLEY E E, et al. Uric acid and hypertension: an update with recommendations[J]. Am J Hyperten, 2020, 33(7): 583-594.
LIANG W Y, ZHU X Y, ZHANG J W, et al. Uric acid promotes chemokine and adhesion molecule production in vascular endothelium via nuclear factor-kappa B signaling[J]. Nutr Metab Cardiovasc Dis, 2015, 25(2): 187-194.
LI S, SUN Z, ZHANG Y, et al. COX-2/mPGES-1/PGE2 cascade activation mediates uric acid-induced mesangial cell proliferation[J]. Oncotarget, 2017, 8(6): 10185-10198.
RYU E S, KIM M J, SHIN H S, et al. Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease[J]. Am J Physiol Renal Physiol, 2013, 304(5): F471-F480.
ANDERS H J, LI Q, STEIGER S. Asymptomatic hyperuricaemia in chronic kidney disease: mechanisms and clinical implications[J]. Clin Kidney J, 2023, 16(6): 928-938.
姜威,徐旻,陈以平.陈以平教授辨治痛风性肾病经验撷菁[J].中国中西医结合肾病杂志, 2021, 22(3): 192-194.
孟元,高彦彬,王雨,等.高彦彬教授从络病论治慢性尿酸性肾病经验[J]. 世界中医药,2020,15(16):2470-2473,2477.
MEI Y, DONG B, GENG Z, et al. Excess uric acid induces gouty nephropathy through crystal formation: A review of recent insights[J]. Front Endocrinol (Lausanne), 2022, 13: 911968.
李明慧,观金,代睿欣,等. 活血利湿降浊方调控尿酸转运体及炎症改善高尿酸血症肾病的研究[J]. 中药药理与临床, 2022, 38(1): 150-155.
王慧超,张威,李铁军. 痛风泄浊方对高尿酸血症的治疗机制[J]. 中医药信息, 2018, 35(4): 59-63.
YANG L, CHANG B, GUO Y, et al. The role of oxidative stress-mediated apoptosis in the pathogenesis of uric acid nephropathy[J]. Ren Fail, 2019, 41(1): 616-622.
徐梅秀,薛丕良,黄芳,等. 基于NADPH/ROS/ERK信号通路探讨肾康降酸颗粒对高尿酸血症大鼠肾小管上皮细胞损伤的作用机制[J].现代中西医结合杂志, 2021, 30(10): 1066-1072.
魏文静,高欣,雷烨,等. 降浊四妙散通过降低血尿酸水平及抑制NLRP3炎症小体对大鼠高尿酸血症及其肾损伤的改善作用研究[J]. 现代生物医学进展, 2023, 23(8): 1436-1441.
吴燕升,李东东,王传旭,等. 矢志方对不同病程高尿酸血症大鼠氧化应激的改善作用[J]. 中华中医药杂志, 2022, 37(1): 487-492.
王骆冰. 复方矢志方对老年尿酸性肾病患者氧化应激的影响[J].中国老年学杂志, 2016, 36(18): 4556-4558.
SONG X, SUN Z, CHEN G, et al. Matrix stiffening induces endothelial dysfunction via the TRPV4/microRNA-6740/endothelin-1 mechanotransduction pathway[J]. Acta Biomater, 2019, 100: 52-60.
TSUPRYKOV O, CHAYKOVSKA L, KRETSCHMER A, et al. Endothelin-1 overexpression improves renal function in eNOS knockout mice[J]. Cell Physiol Biochem, 2015, 37(4): 1474-1490.
COELHO S C, BERILLO O, CAILLON A, et al. Three-month endothelial human Endothelin-1 overexpression causes blood pressure elevation and vascular and kidney injury[J]. Hypertension, 2018, 71(1): 208-216.
李亚芹,韩璇,刘文敏. 当归补血汤对高尿酸血症大鼠肾组织NO、NOS、ET及PAI-1水平的影响[J]. 山东医药, 2010, 50(12): 32-34.
李宇轩,李笑,于学成,等. 当归拈痛汤对高尿酸血症性肾病小鼠肾脏保护作用的研究[J].陕西中医, 2019, 40(9): 1155-1157, 1225.
郭亚芳,丁铃,乔春萍,等. 降尿酸方对高尿酸血症肾病大鼠内皮功能的影响[J]. 世界中医药, 2022, 17(7): 965-969,976.
MISAWA T, TAKAHAMA M, KOZAKI T, et al. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome[J]. Nat Immunol, 2013, 14(5): 454-460.
JOOSTEN L A, NETEA M G, MYLONA E, et al. Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis[J]. Arthritis Rheum, 2010, 62(11): 3237-3248.
TEODORO T B, FERNANDA M F, MATHEUS C, et al. Soluble Uric Acid Activates the NLRP3 Inflammasome[J]. Sci Rep, 2017, 7: 39884.
WANG J, BU X, QIU X, et al. Qinling liquid ameliorates renal immune inflammatory damage via activating autophagy through AMPK/Stat3 pathway in uric acid nephropathy[J]. Cytokine, 2023, 163: 156120.
相瑞阳,张正菊,杨蕾,等.秦苓液对尿酸性肾病大鼠肾组织NLRP3信号途径的影响[J].世界中西医结合杂志, 2020, 15(5): 872-879.
李东东,刘伟伟,周子正,等. 基于TLR4/NF-κB信号通路的降尿酸方对尿酸性肾病大鼠肾功能和尿酸盐结晶的影响[J].中国中医药信息杂志, 2021, 28(9): 56-61.
曹文洁,黄林生,刘丽,等. 甘草黄酮醇降尿酸及抑制氧化应激作用及其机制研究[J]. 中国现代应用药学, 2023, 40 (4): 448-454.
谭珊,郭振宇,陈程,等.基于URAT1蛋白表达研究小檗碱对高尿酸血症小鼠炎症反应及氧化应激的影响[J].现代药物与临床, 2023, 38(1): 16-21.
张永怡,吴家超,李水萍,等. 民族药肾茶的化学成分与药理作用研究进展[J]. 中医药学报, 2021, 49(1): 112-120.
南京中医药大学. 中药大辞典[M]. 上海:上海科学技术出版社, 2006: 3081-3082.
PARKER J L, KATO T, KUTEYI G, et al. Molecular basis for selective uptake and elimination of organic anions in the kidney by OAT1[J]. Nat Struct Mol Biol, 2023, 30(11): 1786-1793.
MUSIAŁ K, STOJANOWSKI J, MIŚKIEWICZ-BUJNA J, et al. KIM-1, IL-18, and NGAL, in the machine learning prediction of kidney injury among children undergoing hematopoietic stem cell transplantation—A pilot study[J]. Int J Mol Sci, 2023, 24(21): 15791.
AABERG-JESSEN C, SØRENSEN M D, MATOS A L S A, et al. Co-expression of TIMP-1 and its cell surface binding partner CD63 in glioblastomas[J]. BMC Cancer, 2018, 18(1): 270.
蓝伦礼. 肾茶对高尿酸血症及痛风性肾病肾损害的保护作用及机制研究[D]. 广州:广州中医药大学, 2016.
陈冲,曾臣红,张斯琪,等.萆薢的研究进展[J].中国中药杂志, 2017, 42(18): 3488-3496.
苏筠霞,李建华,刘天喜,等.萆薢水提物对尿酸性肾病大鼠TNF-α、MCP-1和ICAM-1表达的影响[J].中成药, 2013, 35(5): 1088-1091.
韩思琪,哈伟,师彦平.大黄及其有效成分抗炎作用的研究进展[J].中草药, 2023, 54(1): 303-316.
杨秀飞,黄传兵,徐慧敏,等.大黄治疗痛风的作用机制研究进展[J].湖北中医杂志, 2018, 40(4): 54-57.
CHANG W C, CHU M T, HSU C Y, et al. Rhein,an anthraquinone drug,suppresses the NLRP3 inflammasome and macrophage activation in urate crystal-induced gouty inflammation[J]. Am J Chin Med,2019, 47(1): 135-151.
林思,秦慧真,邓玲玉,等. 虎杖苷药理作用及机制研究进展[J].中国实验方剂学杂志, 2021, 27(22): 241-250.
SHI X,ZHUANG L, ZHAI Z, et al. Polydatin protects against gouty nephropathy by inhibiting renal tubular cell pyroptosis[J]. Int J Rheum Dis, 2023, 26(1): 116-123.
卢美琪,徐万爱,于欢.车前子的炮制历史沿革、化学成分及药理作用研究进展[J].中国中药杂志,2024[2024-05-10]. https://doi.org/10.19540/j.cnki.cjcmm.20240422.201https://doi.org/10.19540/j.cnki.cjcmm.20240422.201.
徐硕,徐文峰,梁晓丽,等. 车前子的化学成分及生物活性研究进展[J]. 西北药学杂志, 2019, 34(4): 567-570.
ZHAO H, XU J, WANG R, et al. Plantaginis Semen polysaccharides ameliorate renal damage through regulating NLRP3 inflammasome in gouty nephropathy rats[J]. Food Funct, 2021, 12(6): 2543-2553.
姜平,吴心瑶,杜星辰,等. 基于数据挖掘、网络药理学的中医药治疗痛风遣方用药规律和作用机制[J]. 上海中医药杂志, 2023, 57(4): 72-82.
BADVE S V, PASCOE E M, TIKU A, et al. Effects of allopurinol on the progression of chronic kidney disease[J]. N Engl J Med, 2020, 382(26): 2504-2513.
0
浏览量
0
下载量
0
CSCD
0
CNKI被引量
关联资源
相关文章
相关作者
相关机构